Compounds > 1-hexadecyl-2-acetyl-glycero-3-phosphocholine
Page last updated: 2024-09-02

1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Heart Defects, Congenital

1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with Heart Defects, Congenital in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ereth, MH; Harmsen, WS; Klindworth, JT; MacVeigh, I; Nuttall, GA; Oliver, WC; Orszulak, TA; Santrach, PJ1
Gillespie, K; Jamieson, WR; Marier, JR; McGibbon, R; Mickleson, H; Sadeghi, H; Zhang, J1
Andrew, M; Coles, J; Rabinovitch, M; Trusler, GA; Turner-Gomes, SO; Williams, WG1

Other Studies

3 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Heart Defects, Congenital

ArticleYear
Does the platelet-activated clotting test (HemoSTATUS) predict blood loss and platelet dysfunction associated with cardiopulmonary bypass?
    Anesthesia and analgesia, 1997, Volume: 85, Issue:2

    Topics: Adult; Blood Coagulation; Blood Coagulation Tests; Blood Loss, Surgical; Blood Platelets; Cardiopulmonary Bypass; Coronary Artery Bypass; Female; Forecasting; Heart Defects, Congenital; Heart Valves; Heparin Antagonists; Humans; Male; Mediastinum; Partial Thromboplastin Time; Platelet Activating Factor; Platelet Activation; Platelet Count; Point-of-Care Systems; Postoperative Hemorrhage; Protamines; Prothrombin Time; Reoperation; Retrospective Studies; Sensitivity and Specificity; Thrombelastography

1997
Strategies of myocardial protection for operation in chronic model of cyanotic heart disease.
    The Annals of thoracic surgery, 1998, Volume: 66, Issue:5

    Topics: Animals; Cardiopulmonary Bypass; Chronic Disease; Disease Models, Animal; Filtration; Heart; Heart Arrest, Induced; Heart Defects, Congenital; Injections, Intravenous; Lymphocyte Depletion; Myocardial Contraction; Platelet Activating Factor; Pyridinium Compounds; Swine

1998
Abnormalities in von Willebrand factor and antithrombin III after cardiopulmonary bypass operations for congenital heart disease.
    The Journal of thoracic and cardiovascular surgery, 1992, Volume: 103, Issue:1

    Topics: Antithrombin III; Cardiopulmonary Bypass; Child; Follow-Up Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Platelet Activating Factor; Postoperative Complications; Protein C; Pulmonary Embolism; von Willebrand Factor

1992